在加拿大，大学生应该接种脑膜炎球菌疾病疫苗吗？
Should university students be vaccinated against meningococcal disease in Canada?
作者信息
De Wals Philippe
机构信息
Department of Social and Preventive Medicine, Laval University and National Institute of Public Health, Quebec City, Quebec.
出版信息
Can J Infect Dis. 2004 Jan;15(1):25-8. doi: 10.1155/2004/740537.
OBJECTIVE
To evaluate the benefit and costs of vaccination of university students against invasive meningococcal disease (IMD) in Canada.
METHODS
Published studies were reviewed and a simulation model was used.
RESULTS
IMD risk seems to be of low magnitude, but consequences can be dramatic. Over a 10-year period, IMD risk reduction would be slightly greater using a monovalent C conjugate vaccine than a quadrivalent polysaccharide vaccine. From a societal perspective, costs per quality-adjusted life-years gained would be between $135,000 and $698,000, according to epidemiological scenarios and with vaccine purchase prices between $35 and $50 per dose.
CONCLUSIONS
Economic indices exceed proposed criteria for cost effective public health programs, but from the perspective of students and parents, the cost of vaccination might be worth the benefit.
目的
评估加拿大大学生接种侵袭性脑膜炎球菌病（IMD）疫苗的效益和成本。
方法
对已发表的研究进行综述并使用模拟模型。
结果
IMD风险似乎较低，但后果可能很严重。在10年期间，使用单价C结合疫苗降低IMD风险的效果略优于四价多糖疫苗。从社会角度来看，根据流行病学情况以及每剂疫苗购买价格在35美元至50美元之间，每获得一个质量调整生命年的成本在135,000美元至698,000美元之间。
结论
经济指标超过了具有成本效益的公共卫生项目的提议标准，但从学生和家长的角度来看，接种疫苗的成本可能物有所值。
Zotero 插件